Continuing the endocannabinoid system series. Previously: Anandamide — Unlocking the Bliss Molecule and Your Body Makes Its Own Cannabis — And Running Is the Key That Unlocks It. This week: what happens when the system breaks.
When the System Breaks — What Fibromyalgia Reveals About the Endocannabinoid System and Why It Matters
A 2025 peer-reviewed review has mapped the relationship between fibromyalgia and the endocannabinoid system in detail. The findings suggest that what millions experience as widespread chronic pain may be, at least in part, a disease of endocannabinoid deficiency.
Over the past two weeks we have been building a picture of the endocannabinoid system from the inside out. We looked at anandamide — the bliss molecule — what it is, where it comes from, and what it does in the brain and body. Then we looked at what happens when you run at the right intensity, and how moderate exercise triggers your body's own endocannabinoid release — reducing anxiety, elevating mood, and producing effects that closely mirror what cannabis achieves pharmacologically.
This week we arrive at the darker side of the same story. What happens when the endocannabinoid system doesn't work properly? What does a chronically dysregulated endocannabinoid system look like from the outside — as experienced by a real person, in a real body, every day?
A 2025 review published in Current Issues in Molecular Biology by Mario García-Domínguez at the Universidad de Navarra provides one of the most comprehensive analyses to date of the endocannabinoid system's role in fibromyalgia. It connects everything we have covered in the last two weeks — the receptors, the molecules, the signalling cascades — to a clinical condition affecting hundreds of millions of people worldwide. Understanding this connection matters for anyone trying to understand what cannabis is actually doing in the human body, and why.
What Fibromyalgia Is — And Why It Has Been So Hard to Explain
Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, persistent fatigue, sleep disturbances, and cognitive impairments — a cluster that includes difficulty with memory and concentration often called fibrofog. The pain varies in intensity and location and is linked to sensitivity at specific areas known as tender points.
Widespread Pain
Musculoskeletal pain across multiple body regions, linked to sensitivity at tender points. Varies in intensity and location, often described as burning, aching, or stabbing.
Persistent Fatigue
Chronic exhaustion that is not relieved by rest, often described as profound and disproportionate to any physical activity undertaken.
Sleep Disturbance
Non-restorative sleep, difficulty maintaining sleep, and frequent waking — creating a cycle where poor sleep worsens pain sensitivity and pain disrupts sleep.
Fibrofog
Cognitive impairments including memory loss, difficulty concentrating, and slowed mental processing — often as debilitating as the physical symptoms.
It affects 6.4% of the US population and between 2.4% and 3.3% in Europe and South America — significantly more prevalent in women. It is not rare. It is one of the most common chronic pain syndromes on the planet, affecting hundreds of millions of people globally.
What has made fibromyalgia so difficult to treat, and historically so difficult to take seriously in medical settings, is that its underlying mechanisms have resisted clear explanation. There is no obvious tissue damage visible on scans. There is no single biomarker. For decades, patients were told the pain was psychological. The condition was real and debilitating, but the biology behind it was opaque. What is now emerging from the research is a different picture. The problem may not be in the joints or muscles themselves. The problem may be in the system responsible for regulating how pain signals are processed, amplified, and dampened — and that system is the endocannabinoid system.
The Clinical Endocannabinoid Deficiency Hypothesis
The central theoretical framework the review examines is called Clinical Endocannabinoid Deficiency — CECD. The hypothesis is straightforward: in some individuals, the endocannabinoid system operates chronically below its optimal level. The system that is supposed to modulate pain, regulate sleep, stabilise mood, and dampen inflammation is not producing enough, not signalling effectively, or not maintaining adequate receptor sensitivity. The result is a body that cannot properly regulate its own experience of pain and discomfort.
This hypothesis would explain much of what makes fibromyalgia so puzzling. If the problem is systemic underfunction of the endocannabinoid system — rather than localised tissue damage — then of course there would be no obvious structural abnormality on imaging. The problem would be functional, not structural. The pain would be real, widespread, and variable because the system responsible for dampening and contextualising pain signals across the entire nervous system is impaired.
"If the problem is a systemic underfunction of the endocannabinoid system, then of course there is no structural abnormality on imaging. The problem is functional. The pain is real — the dampening system is what's failing."
The CECD hypothesis also directly connects to the synaptic signalling mechanism we described in the anandamide piece. Endocannabinoids work as retrograde messengers — released by postsynaptic neurons, travelling backwards across the synapse, and binding to presynaptic CB1 receptors to suppress the release of glutamate and other excitatory neurotransmitters. This mechanism is the brain's primary tool for preventing pain signals from being over-amplified. If that tool is impaired, pain signals propagate more freely. The threshold for what feels painful is lowered. Everything hurts more than it should.
What the Endocannabinoid System Is Actually Doing in Pain Regulation
The review provides a detailed account of the endocannabinoid system's role in pain modulation that clarifies precisely why a deficiency in this system would produce the pattern of symptoms seen in fibromyalgia.
ECS Pain Regulation — Key Mechanisms Involved in Fibromyalgia
- Spinal Cord CB1 receptors are present in the dorsal horn — the primary relay station for pain signals entering the central nervous system. Endocannabinoid signalling here suppresses pain transmission before it reaches the brain.
- Fascial Tissue CB1 and CB2 receptors have been identified in fascial tissue — the connective network covering and connecting muscles throughout the body. A direct mechanism by which ECS deficiency could produce the diffuse musculoskeletal pain of fibromyalgia.
- Joint Protection CB1 activation blocks inflammatory degradation of connective tissues. When synovial cells are exposed to the inflammatory cytokine TNF-alpha, they secrete enzymes that degrade cartilage. Anandamide inhibits this process — ECS deficiency removes this protective mechanism.
- Retrograde Brake Endocannabinoids released by postsynaptic neurons travel backwards across synapses to suppress further excitatory neurotransmitter release. This is the nervous system's volume control on pain. When this brake is compromised, pain sensitisation is amplified system-wide.
The Paradox in the Blood Data
Here is where the research becomes genuinely counterintuitive — and requires careful interpretation.
Several studies cited in the review have measured circulating endocannabinoid levels in fibromyalgia patients and found them to be elevated, not depleted. Anandamide concentrations were significantly higher in fibromyalgia patients than in healthy controls. Levels of 2-AG, OEA, PEA, and SEA — related endocannabinoid-like molecules — were also increased. At first glance this seems to contradict the deficiency hypothesis. If endocannabinoid levels are higher in fibromyalgia patients, how can the condition be caused by deficiency?
The review interprets the elevated blood levels as a probable compensatory response — the system producing more of these molecules in response to inadequate function at the receptor level. The same phenomenon is well known in other hormonal systems: when receptors become less responsive, the body increases production of the signalling molecule in an attempt to compensate. The elevated circulating levels may reflect not abundance but distress — a body working harder than it should to achieve an effect it is struggling to produce.
This interpretation is also consistent with the exercise research from last week. Long-term regular exercise was associated with decreased baseline endocannabinoid levels — the body adapting by upregulating FAAH, the enzyme that degrades anandamide, in response to repeated elevation. A body chronically producing excess endocannabinoids as a compensatory response may develop a similar pattern of accelerated degradation, creating a cycle that perpetuates the deficiency rather than correcting it.
The Menstrual Cycle Connection
One of the most striking findings in the review involves the relationship between the menstrual cycle and fibromyalgia diagnosis. It illuminates the endocannabinoid system's hormonal sensitivity in ways with real clinical implications.
Anandamide levels fluctuate across the menstrual cycle in healthy women. During the follicular phase — the first half — AEA levels are relatively high. During the luteal phase — the second half — progesterone upregulates FAAH, the anandamide-degrading enzyme, causing AEA levels to fall. A study found that this drop in anandamide during the luteal phase was associated with significantly increased sensitivity to pressure pain. And in a particularly striking finding: some participants met the diagnostic criteria for fibromyalgia during the luteal phase — the low-AEA phase — but not during the follicular phase, when AEA was higher.
This is not a peripheral observation. It suggests that the boundary between fibromyalgia and normal pain sensitivity may, for some individuals, be a matter of endocannabinoid tone — and that tone fluctuates with hormonal cycles. It may help explain the significantly higher prevalence of fibromyalgia in women. It also opens a question about whether hormonal fluctuations more broadly interact with endocannabinoid function in ways that contribute to chronic pain vulnerability across multiple conditions.
The Sleep Dimension
The review addresses the endocannabinoid system's role in sleep regulation — directly relevant to fibromyalgia because sleep disturbance is one of its most disabling features.
The pineal gland produces both melatonin and 2-AG in a circadian rhythm, partially regulated through CB2 receptor activation in the suprachiasmatic nucleus — the brain's master clock. Anandamide has also been shown to play a role in sleep onset. In a person with endocannabinoid deficiency, both the sleep regulatory function and the pain modulatory function would be impaired simultaneously.
The characteristic pattern of fibromyalgia — pain that worsens with poor sleep, and sleep that is disrupted by pain — may not be two separate problems feeding each other. It may be one problem: a dysregulated endocannabinoid system failing at both pain regulation and sleep regulation at the same time, from the same underlying deficiency.
What Cannabis-Based Therapies Have Shown
The review surveys the clinical evidence for cannabis-based treatments in fibromyalgia, covering studies from 2011 to 2024. The picture is promising but not yet definitive.
Clinical Evidence — Key Study Findings
- 2019 study: 50% reduction in pain intensity in 81% of fibromyalgia patients after six months of medical cannabis treatment
- Israeli survey: 94% reported pain relief, 93% improved sleep, 87% reduced depressive symptoms, 62% reduced anxiety
- 2024 study: cannabis combined with oxycodone reduced opioid consumption by 35% without affecting cannabis use frequency
- 2024 low-dose medical cannabis study: substantial reduction in pain intensity and improvements in physical and mental state in the majority of participants
- Nabilone (synthetic cannabinoid): significant reductions in pain, anxiety, and overall fibromyalgia impact in randomised controlled trials
- Systematic review of 17 studies (2021): cannabis-based medicines may be effective for pain relief and sleep improvement — moderate quality evidence
The anti-inflammatory properties of CBD combined with the analgesic and muscle-relaxant properties of THC appear to produce a synergistic effect across fibromyalgia's multiple symptom domains. This is biologically coherent — the condition involves dysregulation across pain, mood, sleep, and inflammation, and a therapy that modulates the endocannabinoid system broadly would be expected to address multiple symptoms simultaneously rather than one in isolation.
The honest limitation is that most of this evidence comes from observational studies, surveys, and small trials. Randomised controlled trials with large sample sizes and long follow-up periods are largely absent. The evidence is promising and biologically well-motivated, but it is not yet at the standard required to establish definitive clinical guidelines. Patients should consult healthcare professionals before considering cannabis as a treatment, as individual responses can vary significantly.
What This Means for the Cannabis Community
The fibromyalgia research adds a critical dimension to the understanding of cannabis that this series has been building week by week.
We established that the endocannabinoid system is the body's own regulatory network — producing anandamide and 2-AG to manage pain, mood, sleep, anxiety, and inflammation. We established that exercise activates this system. This week's paper adds: when this system chronically underperforms, the result is not just a mildly worse baseline mood. The result can be a debilitating condition — widespread pain, exhaustion, cognitive impairment, and disrupted sleep — affecting millions of people who often spend years being told nothing is physically wrong with them.
Cannabis, in this context, is not a recreational novelty or a pharmaceutical shortcut. It is a plant-derived intervention targeting a specific physiological system that, in a significant proportion of the population, is not functioning adequately. The CB1 and CB2 receptors that THC and CBD interact with are the same receptors that are failing to do their job in fibromyalgia patients. The anandamide that cannabis mimics is the same molecule that fluctuates with the menstrual cycle and drops to a level that temporarily meets the diagnostic threshold for fibromyalgia.
"For many people in genuine physiological distress, cannabis may not be making them high. It may be making them feel normal — because it is restoring a function the body is struggling to maintain on its own."
This is what understanding the endocannabinoid system means in practice. Not just a more sophisticated explanation for why cannabis makes some people feel good. A clearer picture of why, for many people in genuine physiological distress, it may be making them feel normal — because it is restoring a function the body is struggling to maintain on its own.
The Endocannabinoid System Series — The Grower's Connect
- Part 01 → Anandamide — Unlocking the Bliss Molecule
- Part 02 → Your Body Makes Its Own Cannabis — And Running Is the Key That Unlocks It
- Part 03 → When the System Breaks — What Fibromyalgia Reveals About the Endocannabinoid System — You're reading it
